ESTRO 36 Abstract Book

S207 ESTRO 36 _______________________________________________________________________________________________

intra-fraction monitoring, dose accumulation / reconstruction and perhaps dose adaptation? Current research which aims to overcome these limitations will be highlighted.

team member should be aware of the each other’s qualifications and limitations. Institutional experience has been demonstrated to affect outcome in radiotherapy for early and local advanced stage NSCLC forming the rational for more centralized lung cancer care. Treatment decision making should be performed in multi-disciplinary tumor boards. Concomitant radio-chemotherapy is recommended in all appropriately selected patients with locally advanced NSCLC but only little progress has been made in this field: whereas new a large number of new drugs have made their way into treatment of stage IV NSCLC (EGFR inhibitors, ALK inhibitors, immunotherapy) none has been approved as combination partner with radiotherapy, yet. Imaging for staging and target volume definition should be stage and location adapted including CT with or w/o IV contrast, FDG-PET CT and consider information from endoscopic staging. A motion compensation strategy is required for all patients with respiration correlated 4D-CT imaging forming the basis; there are no clinically significant differences in the specific motion compensation strategy. Treatment planning using static or dynamic rotational intensity modulated techniques have largely replaced 3D conformal techniques especially in complex shaped early stage and locally advanced stage of disease. Risk adapted fractionation is standard in stereotactic body radiotherapy for early stage NSCLC and total doses need to be >100Gy BED. Based on the RTOG 0617 trial, conventionally fractionated doses of 60 – 66Gy remain a standard of care and further dose escalation should only be performed in centers with sufficient expertise. Image-guided treatment delivery is highly recommended in curative treatment for lung cancer. Adaptive re-planning is frequently necessary in case of larger anatomical changes. Adaptive re-planning for a shrinking tumor is technically challenging and may reduce doses to organs at risk especially in patients with very large tumor volumes, where a curative dose is otherwise hard to achieve. Follow-up and evaluation of the institutional specific results are important components of all quality assurance systems. SP-0386 How to write a research proposal for a grant? P. Lambin 1 1 MAASTRO Clinic, Maastricht, The Netherlands Introduction: Financial resources from Universities are cut down and scientists are more often expected to fund their own research. There are different phases in the process of writing grants, summarized hereunder: Step 0: Identify what your expertise is in which you will have convincing papers and/ore preliminary data. Screen the possible grants for scientific research regularly. (6-12 months before the deadline for submission) Step 1: When you have identified grants that are suitable for your work, try to get as much information as possible about the grant itself. Identify the (best) partners that you will need for your research project, especially in the case of proposals for the European Commission. Step 2: Write a skeleton of the research proposal with brief concepts, hypothesis objective and keywords for each of the main parts of the proposal. This should be completed at least 3 months before the deadline for submission. Before doing too much work, discuss it with experts and colleagues of your departments. It is easy at this point to make big changes in the structure of the proposal, but very difficult after much of the writing has been done. A research proposal consists of several parts: Background ( Problem definition): insist on the “why” you want to do this. Teaching Lecture: How to write a research proposal for a grant?

Teaching Lecture: Radiomics for physicists – understanding feature extraction, modelling, performance validation and applications of radiomics

SP-0384 Radiomics for physicists – understanding feature extraction, modelling, performance validation and applications of radiomics S. Walsh 1 1 MAASTRO Clinic, Maastricht, The Netherlands The field of radiomics, the high-throughput mining of quantitative image features from (standard-of-care) medical imaging for knowledge extraction and application within clinical decision support systems to improve diagnostic, prognostic, and predictive accuracy, offers significant and substantial advances for the medical community. Radiomics utilizes advanced image analysis/machine-learning techniques coupled with the explosion of medical imaging data to develop and validate potent quantitative imaging biomarkers (QIB) for precision medicine. This lecture describes the practice of radiomics, its hazards, challenges/opportunities, and its potential to support clinical decision making (currently predominantly in oncology, however, all imaged patients may benefit from QIBs). Lastly, the discipline of radiomics is developing swiftly; though it is absent standardized evaluation of both the scientific veracity and the clinical importance of published radiomics investigations. There is an obvious and evident need for rigorous evaluation criteria and reporting strategies to guarantee that radiomics fulfills its promise. To this end for both retrospective and prospective studies, the radiomics quality score (RQS: www.radiomics.org) and an online digital phantom (DOI: 10.17195/candat.2016.08.1) are offered to provide guidance and help meet this need in the field of radiomics.

Teaching Lecture: Focus on lung cancer: What a radiotherapy department should offer their patients

SP-0385 Focus on lung cancer: What a radiotherapy department should offer their patients M. Guckenberger 1 1 University Hospital Zürich, Department of Radiation Oncology, Zurich, Switzerland After years of stagnation, the treatment of lung cancer has recently advanced tremendously. This rapid progress is associated with new challenges and requirements on the optimal radio-oncological care of lung cancer. Most importantly, radiotherapy for lung cancer needs to be integrated into a multi-disciplinary and multi-professional team involving medical oncology, pulmonology, thoracic surgery, radiation oncology, pathology, radiology, nuclear medicine, psycho-oncology and palliative care. National and international guidelines need to form the basis for development of institutional specific guidelines and each